Trilaciclib Dihydrochloride
Trilaciclib dihydrochloride is the dihydrochloride salt form of trilaciclib, a CDK4/6 inhibitor that transiently induces G1 cell cycle arrest in hematopoietic progenitor cells to protect bone marrow during chemotherapy. It reduces the need for granulocyte colony-stimulating factor and red blood cell transfusions following myelosuppressive chemotherapy. This salt form is used in the clinical formulation of the intravenous product.
Peso Molecular
519,5000 g/mol
TPSA
91,20 Ų
Áreas Terapêuticas
Mecanismo de Ação
Selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), blocking the phosphorylation of retinoblastoma protein and arresting the cell cycle at the G1/S transition to prevent cancer cell proliferation.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), blocking the phosphorylation of retinoblastoma protein and arresting the cell cycle at the G1/S transition to prevent cancer cell proliferation.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1.Cl.Cl
InChI
InChI=1S/C24H30N8O.2ClH/c1-30-9-11-31(12-10-30)18-5-6-20(25-15-18)28-23-26-14-17-13-19-22(33)27-16-24(7-3-2-4-8-24)32(19)21(17)29-23;;/h5-6,13-15H,2-4,7-12,16H2,1H3,(H,27,33)(H,25,26,28,29);2*1H
Molecular Formula
C24H32Cl2N8O
HBD / HBA
4 / 7
Ligações Rotacionáveis
3
Átomos Pesados
35
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
Trilaciclib dihydrochloride is the dihydrochloride salt form of trilaciclib, a CDK4/6 inhibitor that transiently induces G1 cell cycle arrest in hematopoietic progenitor cells to protect bone marrow during chemotherapy. It reduces the need for granulocyte colony-stimulating factor and red blood cell transfusions following myelosuppressive chemotherapy. This salt form is used in the clinical formulation of the intravenous product.
Selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), blocking the phosphorylation of retinoblastoma protein and arresting the cell cycle at the G1/S transition to prevent cancer cell proliferation.
Yes, Trilaciclib Dihydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4650272. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 124081865. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="trilaciclib-dihydrochloride"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/trilaciclib-dihydrochloride/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/trilaciclib-dihydrochloride/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/trilaciclib-dihydrochloride/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="trilaciclib-dihydrochloride"></drugfyi-drug>